Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf
Lung-EPICLIN/G
1 other identifier
observational
25
3 countries
3
Brief Summary
The overall aim of the study is: To provide accurate and reliable information regarding NSCLC clinical management across MENA region in order to detect unmet medical needs of this disease in terms of:
- Patient and hospital characteristics.
- Diagnostic and treatment approaches: initial and subsequent.
- Follow-up patterns in clinical management.
- Outcomes: symptoms, death, functionality, quality of life.
- Use of resources and burden on patients and health care systems.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2012
Typical duration for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2012
CompletedFirst Posted
Study publicly available on registry
March 26, 2012
CompletedStudy Start
First participant enrolled
June 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2015
CompletedMay 24, 2016
May 1, 2016
2.7 years
February 22, 2012
May 23, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Use of health resources by collecting data about hospital description and characteristics, Disease Diagnosis Procedures and Therapy information
April 2014(26 Months)
Secondary Outcomes (1)
Patient-Reported Outcomes (PRO) through self-administered questionnaires and the patients will be asked to complete them at each evaluation visit(25% of the whole sample)
April 2014(26 Months)
Study Arms (2)
All Population
Sample of patients will be invited to complete Quality of Life
Eligibility Criteria
Oncology Institutes
You may qualify if:
- Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between November 1st, 2011 and August 30th, 2012 For PRO
- Sub-sample:
- ability to read and write since they will be asked to participate in the PRO part of the study.
- Selection will not be based on the disease stage of each patient, in order to avoid a selection bias.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (3)
Research Site
Manama, Bahrain
Research Site
Doha, Qatar
Research Site
Alain - AbuAhabi, United Arab Emirates
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Kakil Rasul, CONSULTANT
Hamad Medical Corporation, Doha, Qatar
- PRINCIPAL INVESTIGATOR
Ahmed El Khodary, CONSULTANT
Kuwait Cancer Centre, Al Sabah Hospital, Kuwait
- PRINCIPAL INVESTIGATOR
Norbert Drier, CONSULTANT
Zayed Military Hospital, Abu Dhabi, United Arab Emirates
- PRINCIPAL INVESTIGATOR
Farid Khalifa, CONSULTANT
Salmaniya Medical Complex, Bahrain
- PRINCIPAL INVESTIGATOR
Mohamed Jaloudy, CONSULTANT
Tawam Hospital ,Alain,Abu Dhabi, United Arab Emirates
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2012
First Posted
March 26, 2012
Study Start
June 1, 2012
Primary Completion
February 1, 2015
Study Completion
February 1, 2015
Last Updated
May 24, 2016
Record last verified: 2016-05